SCPS - Scopus Bio names Dr. Alan Horsager as President following acquisition of immunotherapy firm

Scopus BioPharma (SCPS) announces a new appointment following acquisition of immunotherapy company, Olimmune.Alan Horsager, Ph.D., President and CEO of Olimmune, was appointed President of Scopus with responsibility for overseeing the development of the Company’s immuno-oncology pipeline.In his new role, Dr. Horsager assumes certain responsibilities of Ashish P. Sanghrajka. Dr. Horsager previously served as the Director of LA BioSpace at Cal State LA, the university’s initiative to promote bioscience venture creation in Los Angeles.Previously, Dr. Horsager co-founded and served as a senior executive of two biotechnology companies and also served as a Research Assistant Professor at the University of Southern California.

For further details see:

Scopus Bio names Dr. Alan Horsager as President following acquisition of immunotherapy firm